세계의 세포 분리 시장 예측(-2029년) : 시장 규모, 점유율, 동향 : 제품별, 세포 유형별, 세포원별, 기술별, 용도별

The cell isolation market is expected to grow to USD 8.4 billion by 2029, up from USD 4.6 billion in 2024, at a CAGR of 12.9% between 2024 and 2029. Several significant factors contribute to the cell isolation market's potential growth. Government support for cell-based research is increasing, as is the prevalence of cancer and infectious disorders. Furthermore, there is a growing focus on technological developments and personalized medicine. Furthermore, emerging countries provide significant development opportunities, and the increased emphasis on next-generation treatments is expected to drive the market further.

"The biomedical isolation segment accounted for the largest share of by application segment in 2023."

In 2023, the biomedical isolation segment held the largest share of the global cell isolation market by application. Cell isolation is an important process for isolating biomolecules as it allows researchers to focus on specific cell populations and extract target molecules for further analysis, characterization, and use in therapeutic or research applications. Major factors driving the growth of the cell isolation market for biomolecule isolation are the increasing demand for biopharmaceutical products for the treatment of infectious and chronic diseases, innovative and advanced applications of cell analysis techniques in biomolecule isolation, and the growth of the global biopharmaceutical industry.

"In 2023, the US remained to dominate the cell isolation market."

The US dominated the North American cell isolation market in 2023. The US is the world's largest biopharmaceutical market and the leader in biopharmaceutical research and investment. The United States also has a strong healthcare infrastructure, which encourages research and development in the life sciences. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, growing focus on development of cell-based research due to growing prevalence of cancer is also driving the growth of the cell isolation market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America - 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

• Merck KGaA (Germany)
• Danaher Corporation (US)
• Thermo Fisher Scientific Inc. (US)
• BD (US)
• Agilent Technologies, Inc. (US)
• Miltenyi Biotec (Germany)
• Revvity (US)
• Sartorius AG (Germany)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Lonza (Switzerland)
• QIAGEN (Netherlands)
• ALFA LAVAL (Sweden)
• Terumo Corporation (Japan)
• Corning Incorporated (US)
• Bio-Rad Laboratories, Inc. (US)
• GenScript (US)
• Bio-Techne (US)
• Takara Bio Inc. (Japan)
• Standard BioTools (US)
• Promega Corporation (US)
• Cell Signaling Technology, Inc. (US)
• STEMCELL Technologies (Canada)

Research Coverage:

This research report categorizes the cell isolation market by product (consumables (reagents, kits, media & sera, beads (magnetic beads and fluroscent beads), and disposables) and instruments(centrifuges, cell sorters, magnetic-activated cell seperator systems, and filtration systems)), cell type (human cells (differentiated cells and stem cells) and animal cells), cell source (adipose tissues, bone marrow, cord blood/ embryonic stem cells, and others), technique (centrifugation-based cell isolation, surface-based cell isolation, and filtration-based cell isolation), application (biomolecule isolation, cancer research, stem cell research, tissue regeneration & regenerative medicine, in-vitro diagnostics, and others), end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostic laboratories, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell isolation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the cell isolation market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell isolation market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (surge in cases of cancer and infectious diseases and growing emphasis on technological advancements), restraints (ethical & safety issues and high cost of cell-based research), opportunities (growing focus on next generation sequencing), and Challenges (technical complexities and standardization issues) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the cell isolation market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell isolation market
• Competitive Assessment: . Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), BD (US), Agilent Technologies, Inc. (US), Miltenyi Biotec (Germany), Revvity (US), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Lonza (Switzerland), QIAGEN (Netherlands), ALFA LAVAL (Sweden), Terumo Corporation (Japan), Corning Incorporated (US), Bio-Rad Laboratories, Inc. (US), GenScript (US), Bio-Techne (US), Takara Bio Inc. (Japan), Standard BioTools (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), and STEMCELL Technologies (Canada), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS COVERED
  • 1.3.2 REGIONS COVERED
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
    • 1.3.4.1 Value unit
    • 1.3.4.2 Volume unit
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES
• 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION METHODOLOGY
  • 2.2.1 BOTTOM-UP APPROACH
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS
• 2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CELL ISOLATION MARKET OVERVIEW
• 4.2 NORTH AMERICAN CELL ISOLATION MARKET, BY TYPE AND COUNTRY
• 4.3 CELL ISOLATION MARKET SHARE, BY APPLICATION
• 4.4 CELL ISOLATION MARKET SHARE, BY END USER
• 4.5 CELL ISOLATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing government funding for cell-based research
    • 5.2.1.2 Surge in cases of cancer and infectious diseases
    • 5.2.1.3 Rising emphasis on technological advancements and product developments
    • 5.2.1.4 Growing focus on personalized medicine
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Ethical and safety issues
    • 5.2.2.2 High cost of cell-based research
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging economies
    • 5.2.3.2 Increasing focus on next-generation therapeutics
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Complex development process of cell therapies
    • 5.2.4.2 Technical complexities and stringent regulatory requirements
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Centrifugation-based techniques
    • 5.4.1.2 Magnetic cell isolation
    • 5.4.1.3 Fluorescence-activated cell sorting
    • 5.4.1.4 Acoustic cell isolation
    • 5.4.1.5 Acoustofluidic cell isolation
    • 5.4.1.6 Microfiltration
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Mass cytometry
    • 5.4.2.2 Cell imaging technologies
    • 5.4.2.3 Artificial intelligence and machine learning
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Single-cell sequencing
    • 5.4.3.2 Clustered regularly interspaced short palindromic repeats and gene editing
    • 5.4.3.3 3D cell culture
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
  • 5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY TECHNIQUE
  • 5.5.3 AVERAGE SELLING PRICE TREND, BY REGION
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 PATENT ANALYSIS
• 5.8 SUPPLY CHAIN ANALYSIS
• 5.9 ECOSYSTEM ANALYSIS
  • 5.9.1 ROLE OF RAW MATERIAL VENDORS
  • 5.9.2 ROLE OF PRODUCT PROVIDERS
  • 5.9.3 ROLE OF END USERS
  • 5.9.4 ROLE OF REGULATORY AUTHORITIES
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 REGULATORY SCENARIO
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • 5.13.2 BUYING CRITERIA
• 5.14 TRADE ANALYSIS
  • 5.14.1 IMPORT DATA FOR HS CODE 382200
  • 5.14.2 EXPORT DATA FOR HS CODE 382200
• 5.15 INVESTMENT AND FUNDING SCENARIO
• 5.16 IMPACT OF GENERATIVE AI ON CELL ISOLATION MARKET

6 CELL ISOLATION MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 REAGENTS, KITS, MEDIA, AND SERA
    • 6.2.1.1 Surge in product launches and repetitive purchases to boost segment growth
  • 6.2.2 BEADS
    • 6.2.2.1 Magnetic beads
      • 6.2.2.1.1 Growing demand in biomedical research and clinical applications to drive market
    • 6.2.2.2 Fluorescent beads
      • 6.2.2.2.1 Increasing use in flow cytometry, cell sorting, and imaging applications to fuel market
  • 6.2.3 DISPOSABLES
    • 6.2.3.1 Growing government investments in research to aid market growth
• 6.3 INSTRUMENTS
  • 6.3.1 CENTRIFUGES
    • 6.3.1.1 Growing use in pharma-biotech industry to boost market
  • 6.3.2 CELL SORTERS
    • 6.3.2.1 Rise in cell-based research initiatives to augment growth
  • 6.3.3 MAGNETIC-ACTIVATED CELL SEPARATOR SYSTEMS
    • 6.3.3.1 Booming use in research for T-cell and stem cell isolation to drive market
  • 6.3.4 FILTRATION SYSTEMS
    • 6.3.4.1 Rising need to ensure Good Manufacturing Practice standards and regulations to boost market

7 CELL ISOLATION MARKET, BY CELL TYPE

• 7.1 INTRODUCTION
• 7.2 HUMAN CELLS
  • 7.2.1 DIFFERENTIATED CELLS
    • 7.2.1.1 Increasing use in disease modeling, regenerative medicine, and gene therapy to fuel growth
  • 7.2.2 STEM CELLS
    • 7.2.2.1 Rise in grants and funding for stem cell research to drive market
• 7.3 ANIMAL CELLS
  • 7.3.1 GROWING INVESTMENTS FOR VACCINE AND DRUG DEVELOPMENT TO SUPPORT GROWTH

8 CELL ISOLATION MARKET, BY CELL SOURCE

• 8.1 INTRODUCTION
• 8.2 ADIPOSE TISSUE
  • 8.2.1 INCREASING APPLICATIONS IN CLINICAL STUDIES AND TRIALS TO DRIVE MARKET
• 8.3 BONE MARROW
  • 8.3.1 GROWING DEMAND FOR TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS TO AID GROWTH
• 8.4 CORD BLOOD/EMBRYONIC STEM CELLS
  • 8.4.1 HIGH THERAPEUTIC POTENCY TO SUPPORT MARKET GROWTH
• 8.5 OTHER CELL SOURCES

9 CELL ISOLATION MARKET, BY TECHNIQUE

• 9.1 INTRODUCTION
• 9.2 CENTRIFUGATION-BASED CELL ISOLATION
  • 9.2.1 RISE IN USE BY BIOTECH AND BIOPHARMACEUTICAL COMPANIES TO FUEL MARKET
• 9.3 SURFACE MARKER-BASED CELL ISOLATION
  • 9.3.1 INCREASING ADOPTION OF MAGNETIC-ACTIVATED CELL SORTING TO PROPEL MARKET
• 9.4 FILTRATION-BASED CELL ISOLATION
  • 9.4.1 NEED FOR AFFORDABLE FILTRATION TECHNIQUE TO DRIVE MARKET

10 CELL ISOLATION MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 BIOMOLECULE ISOLATION
  • 10.2.1 INCREASING DEMAND FOR BIOPHARMACEUTICAL PRODUCTS TO FUEL MARKET
• 10.3 CANCER RESEARCH
  • 10.3.1 GROWING INCLINATION TOWARD DEVELOPING AND MANUFACTURING CANCER TREATMENTS TO DRIVE MARKET
• 10.4 STEM CELL RESEARCH
  • 10.4.1 RISING GRANTS AND FUNDING FOR STEM CELL RESEARCH TO AUGMENT GROWTH
• 10.5 TISSUE REGENERATION & REGENERATIVE MEDICINE
  • 10.5.1 GROWING INITIATIVES FOR RESEARCH IN REGENERATIVE MEDICINE TO SUPPORT MARKET
• 10.6 IN VITRO DIAGNOSTICS
  • 10.6.1 NEED FOR ACCURACY TO IDENTIFY CELL TYPE TO PROPEL MARKET
• 10.7 OTHER APPLICATIONS

11 CELL ISOLATION MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.2.1 INCREASING INVESTMENTS BY KEY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO BOOST MARKET GROWTH
• 11.3 ACADEMIC & RESEARCH INSTITUTES
  • 11.3.1 HIGH GOVERNMENT FUNDING FOR EDUCATIONAL PURPOSES TO FUEL SEGMENT
• 11.4 HOSPITALS & DIAGNOSTIC LABORATORIES
  • 11.4.1 INCREASING NUMBER OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES TO DRIVE MARKET
• 11.5 OTHER END USERS

12 CELL ISOLATION MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 NORTH AMERICA: RECESSION IMPACT
  • 12.2.2 US
    • 12.2.2.1 Rising prevalence of cancer to drive market
  • 12.2.3 CANADA
    • 12.2.3.1 Increased government funding for stem cell and vaccine research to propel market
• 12.3 EUROPE
  • 12.3.1 EUROPE: RECESSION IMPACT
  • 12.3.2 GERMANY
    • 12.3.2.1 Rising interest in biotechnology drugs and applications to aid market growth
  • 12.3.3 UK
    • 12.3.3.1 Increasing prevalence of infectious diseases to drive market
  • 12.3.4 FRANCE
    • 12.3.4.1 Surge in investments in cell biology research activities to drive market
  • 12.3.5 ITALY
    • 12.3.5.1 Rising number of cell biology seminars and conferences to drive market
  • 12.3.6 SPAIN
    • 12.3.6.1 Increasing funding from private and public organizations to aid growth
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 ASIA PACIFIC: RECESSION IMPACT
  • 12.4.2 CHINA
    • 12.4.2.1 Increasing investments in research and technological advancements to boost market
  • 12.4.3 JAPAN
    • 12.4.3.1 Dominant geriatric population to aid market growth
  • 12.4.4 INDIA
    • 12.4.4.1 Growing penetration of healthcare insurance services to propel market
  • 12.4.5 AUSTRALIA
    • 12.4.5.1 Growing emphasis on personalized medicine, biopharmaceuticals, and advanced therapies to fuel market
  • 12.4.6 SOUTH KOREA
    • 12.4.6.1 Rising need for therapeutics to support market growth
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 LATIN AMERICA: RECESSION IMPACT
  • 12.5.2 BRAZIL
    • 12.5.2.1 Need to improve public access to modern healthcare facilities to drive market
  • 12.5.3 MEXICO
    • 12.5.3.1 Favorable trade agreements to support market
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 MIDDLE EAST: RECESSION IMPACT
  • 12.6.2 GCC
    • 12.6.2.1 Saudi Arabia
      • 12.6.2.1.1 Growing focus on Vision 2030 initiatives to boost market
    • 12.6.2.2 UAE
      • 12.6.2.2.1 Rising inclination toward producing high-value specialty drugs to aid market growth
    • 12.6.2.3 Rest of GCC Countries
  • 12.6.3 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 INCREASING PATIENT POPULATION WITH CANCER TO PROPEL MARKET
  • 12.7.2 AFRICA: RECESSION IMPACT

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL ISOLATION MARKET
• 13.3 REVENUE ANALYSIS, 2021-2023
• 13.4 MARKET SHARE ANALYSIS, 2023
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Type footprint
    • 13.5.5.4 Cell type footprint
    • 13.5.5.5 End user footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS
  • 13.9.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 DANAHER CORPORATION
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Deals
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 MERCK KGAA
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
      • 14.1.2.3.2 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 THERMO FISHER SCIENTIFIC INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches
      • 14.1.3.3.2 Deals
      • 14.1.3.3.3 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 BD
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches
      • 14.1.4.3.2 Deals
      • 14.1.4.3.3 Other developments
  • 14.1.5 SARTORIUS AG
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Deals
  • 14.1.6 AGILENT TECHNOLOGIES, INC.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
  • 14.1.7 BIO-RAD LABORATORIES, INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product launches
  • 14.1.8 QIAGEN
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
  • 14.1.9 F. HOFFMANN-LA ROCHE LTD.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
  • 14.1.10 REVVITY
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Other developments
  • 14.1.11 CORNING INCORPORATED
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
  • 14.1.12 LONZA
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product launches
      • 14.1.12.3.2 Deals
  • 14.1.13 BIO-TECHNE
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Deals
      • 14.1.13.3.2 Other developments
  • 14.1.14 TERUMO CORPORATION
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Deals
  • 14.1.15 MILTENYI BIOTEC
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
  • 14.1.16 TAKARA BIO INC.
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products offered
    • 14.1.16.3 Recent developments
      • 14.1.16.3.1 Deals
  • 14.1.17 GENSCRIPT
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products offered
    • 14.1.17.3 Recent developments
      • 14.1.17.3.1 Deals
  • 14.1.18 STANDARD BIOTOOLS
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products offered
  • 14.1.19 ALFA LAVAL
    • 14.1.19.1 Business overview
    • 14.1.19.2 Products offered
    • 14.1.19.3 Recent developments
      • 14.1.19.3.1 Product launches
      • 14.1.19.3.2 Deals
• 14.2 OTHER PLAYERS
  • 14.2.1 PROMEGA CORPORATION
  • 14.2.2 CELL SIGNALING TECHNOLOGY, INC.
  • 14.2.3 MICAREO INC.
  • 14.2.4 APPLIED CELLS INC.
  • 14.2.5 STEMCELL TECHNOLOGIES
  • 14.2.6 CREATIVE BIOARRAY
  • 14.2.7 PROTEINTECH GROUP, INC.
  • 14.2.8 MAGBIO GENOMICS, INC.
  • 14.2.9 AKADEUM LIFE SCIENCES
  • 14.2.10 PLURISELECT LIFE SCIENCE UG (HAFTUNGSBESCHRANKT) & CO. KG
  • 14.2.11 INVENT BIOTECHNOLOGIES, INC.

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS